{"id":476,"date":"2026-10-01T00:07:02","date_gmt":"2026-09-30T23:07:02","guid":{"rendered":"https:\/\/novameds.health\/us\/nad-precursors-and-infusions\/"},"modified":"2026-10-01T09:15:52","modified_gmt":"2026-10-01T13:15:52","slug":"nad-precursors-and-infusions","status":"publish","type":"post","link":"https:\/\/novameds.health\/us\/knowledge-hub\/nad-precursors-and-infusions\/","title":{"rendered":"NAD+ Precursors and Infusions: Cellular Biology, Oral NMN\/NR vs IV NAD+"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Nicotinamide adenine dinucleotide (NAD<sup>+<\/sup>)<\/strong> is a fundamental coenzyme found in every living cell, essential for cellular bioenergetics, mitochondrial ATP production, and DNA repair. Over the last decade, geroscience research has established that intracellular NAD<sup>+<\/sup> concentrations decline precipitously during chronological aging\u2014dropping by an estimated <strong>40% to 60% by mid-adulthood<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This age-related depletion impairs the activity of critical NAD<sup>+<\/sup>-dependent protective enzymes, notably <strong>sirtuins<\/strong> (epigenetic regulators and metabolic sensors) and <strong>poly(ADP-ribose) polymerases (PARPs)<\/strong> (vital for genomic DNA repair).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The commercial health and longevity market has responded with an array of therapies claiming to restore youth-level cellular NAD<sup>+<\/sup>: from oral dietary precursors like <strong>nicotinamide mononucleotide (NMN)<\/strong> and <strong>nicotinamide riboside (NR)<\/strong>, to high-dose <strong>intravenous (IV) NAD<sup>+<\/sup> infusions<\/strong> and subcutaneous injections.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">However, cellular delivery of NAD<sup>+<\/sup> is biologically complex. This article reviews the biochemistry of the NAD<sup>+<\/sup> salvage pathway, evaluates human clinical trial evidence for oral precursors versus IV infusions, explores the primary culprit behind NAD<sup>+<\/sup> degradation (<strong>the CD38 enzyme<\/strong>), and highlights practical safety considerations.<\/p>\n\n\n\n<aside class=\"wp-block-group nm-takeaways is-layout-flow wp-block-group-is-layout-flow\">\n<h2 class=\"wp-block-heading\">Key takeaways<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Essential Coenzyme and Consumed Substrate:<\/strong> NAD<sup>+<\/sup> functions in two distinct biological roles: as a reversible electron carrier (NAD<sup>+<\/sup> \u2194NADH) in mitochondrial glycolysis and the Krebs cycle, and as an <strong>irrevocably consumed signaling substrate<\/strong> for sirtuins (SIRT1\u2013SIRT7), PARP1, and CD38.<\/li><li><strong>The Delivery Paradox:<\/strong> Intact NAD<sup>+<\/sup> is a large, charged dinucleotide molecule (~663 Da) with two phosphate groups, preventing it from crossing intact mammalian cell membranes directly via simple diffusion. In the gut, oral NAD<sup>+<\/sup> is rapidly hydrolyzed into smaller precursors before systemic absorption.<\/li><li><strong>Oral Precursors (NR and NMN):<\/strong> Clinical trials in humans confirm that oral nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are well tolerated and reliably increase whole-blood NAD<sup>+<\/sup> levels by <strong>40% to 100%<\/strong> within 2 to 4 weeks. However, clinical evidence showing that this translates to extended human lifespan or functional disease reversal remains preliminary.<\/li><li><strong>Intravenous (IV) Infusions:<\/strong> IV NAD<sup>+<\/sup> bypasses the digestive tract and elevates plasma NAD<sup>+<\/sup> and its breakdown products rapidly, but infusions trigger acute, uncomfortable adverse symptoms (intense chest tightness, gastrointestinal cramping, flushing, nausea) driven by adenosine receptor activation.<\/li><li><strong>The CD38 Degradation Barrier:<\/strong> Age-related NAD<sup>+<\/sup> depletion is not primarily caused by a failure of cellular synthesis, but by rampant enzymatic degradation driven by the pro-inflammatory ecto-enzyme <strong>CD38<\/strong>, which is upregulated in aging tissues by senescent cell secretomes (SASP).<\/li><\/ul>\n<\/aside>\n\n\n\n<nav class=\"wp-block-group nm-toc is-layout-flow wp-block-group-is-layout-flow\" aria-label=\"Contents\">\n<h2 class=\"wp-block-heading\">Contents<\/h2>\n\n\n\n<ol><li><a href=\"#biochemical-roles-energy-carrier-vs-consumed-signaling-substrate\">Biochemical Roles: Energy Carrier vs Consumed Signaling Substrate<\/a><\/li><li><a href=\"#why-cellular-nad-declines-with-age-the-cd38-pathway\">Why Cellular NAD+ Declines with Age: The CD38 Pathway<\/a><\/li><li><a href=\"#the-nad-salvage-pathway-precursors-compared\">The NAD+ Salvage Pathway: Precursors Compared<\/a><\/li><li><a href=\"#oral-precursors-nr-vs-nmn-human-clinical-evidence\">Oral Precursors (NR vs NMN): Human Clinical Evidence<\/a><\/li><li><a href=\"#intravenous-iv-nad-infusions-science-and-practical-realities\">Intravenous (IV) NAD+ Infusions: Science and Practical Realities<\/a><\/li><li><a href=\"#subcutaneous-and-intramuscular-nad-injections\">Subcutaneous and Intramuscular NAD+ Injections<\/a><\/li><li><a href=\"#safety-profile-methylation-demands-and-oncological-debates\">Safety Profile, Methylation Demands and Oncological Debates<\/a><\/li><li><a href=\"#frequently-asked-questions\">Frequently Asked Questions<\/a><\/li><li><a href=\"#references\">Scientific references<\/a><\/li><\/ol>\n<\/nav>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"biochemical-roles-energy-carrier-vs-consumed-signaling-substrate\">Biochemical Roles: Energy Carrier vs Consumed Signaling Substrate<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">In cellular biochemistry, NAD<sup>+<\/sup> performs two fundamentally different functions:<\/p>\n\n\n\n<pre class=\"wp-block-preformatted nm-diagram\">                                 NAD+ Functions\n                                       \u2502\n         \u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2534\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510\n         \u25bc                                                           \u25bc\nCoenzyme Redox Reactions                                   Enzymatic Consumption\n($NAD^+ \\leftrightarrow NADH$)                         (Degraded to Nicotinamide)\n\u2022 Glycolysis (Cytoplasm)                                \u2022 Sirtuins (SIRT1-7: Epigenetic repair)\n\u2022 Krebs TCA Cycle (Mitochondria)                        \u2022 PARP1 (Genomic DNA strand break repair)\n\u2022 Electron Transport Chain (ATP production)             \u2022 CD38 \/ CD157 (Immune signaling &amp; degradation)\n[ Reversibly Cycled \u2014 Not Lost ]                        [ Irrevocably Destroyed \u2014 Must Be Re-synthesized ]<\/pre>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"1-metabolic-redox-cycling-reversible\">1. Metabolic Redox Cycling (Reversible)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In intermediary metabolism, NAD<sup>+<\/sup> accepts hydride ions to become reduced NADH. NADH then transfers these electrons to Complex I of the mitochondrial respiratory chain to drive oxidative phosphorylation, generating ATP, and is oxidized back to NAD<sup>+<\/sup>. In this pathway, NAD<sup>+<\/sup> molecules are not destroyed; they cycle continuously back and forth thousands of times per minute.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"2-consumptive-signaling-reactions-irreversible-breakdown\">2. Consumptive Signaling Reactions (Irreversible Breakdown)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In contrast, when regulatory enzymes use NAD<sup>+<\/sup>, they do not merely borrow electrons; they <strong>break the covalent glycosidic bond<\/strong>, cleaving the molecule into <strong>nicotinamide (NAM)<\/strong> and an ADP-ribose moiety:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Sirtuins (SIRT1\u2013SIRT7):<\/strong> Deacetylate histones, transcription factors (PGC-1\u03b1, FOXO), and mitochondrial proteins, promoting mitochondrial biogenesis, antioxidant defense, and metabolic resilience.<\/li><li><strong>PARPs (PARP1 and PARP2):<\/strong> Detect single-strand DNA breaks and use NAD<sup>+<\/sup> to assemble poly(ADP-ribose) chains that recruit DNA repair machinery. In states of oxidative stress or UV exposure, PARP activation can consume over 80% of total intracellular NAD<sup>+<\/sup> pools within minutes.<\/li><li><strong>CD38:<\/strong> An ecto-enzyme on immune cells that consumes roughly 100 molecules of NAD<sup>+<\/sup> for every single molecule of cyclic ADP-ribose it synthesizes.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"why-cellular-nad-declines-with-age-the-cd38-pathway\">Why Cellular NAD+ Declines with Age: The CD38 Pathway<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">For many years, scientists assumed that falling NAD<sup>+<\/sup> levels in aging tissues reflected failing enzymatic synthesis. Groundbreaking research published in <em>Cell Metabolism<\/em> demonstrated the opposite: NAD<sup>+<\/sup> synthesis capacity remains relatively intact, but <strong>enzymatic consumption explodes<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The primary culprit is <strong>CD38<\/strong>, a glycoprotein ecto-enzyme expressed primarily on macrophages and immune cells:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>As tissues age, senescent cells accumulate and release a cocktail of pro-inflammatory cytokines (the senescence-associated secretory phenotype, SASP).<\/li><li>SASP factors (specifically IL-6, TNF-\u03b1, and IFN-\u03b3) recruit resident macrophages and drive dramatic <strong>upregulation of CD38 expression<\/strong>.<\/li><li>Upregulated CD38 actively degrades extracellular NAD<sup>+<\/sup> and its precursors (NMN) before they can enter parenchymal cells.<\/li><li>In animal models, knocking out the CD38 gene or inhibiting CD38 with small molecules preserves tissue NAD<sup>+<\/sup> concentrations into old age and protects against metabolic dysfunction.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"the-nad-salvage-pathway-precursors-compared\">The NAD+ Salvage Pathway: Precursors Compared<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Because <em>de novo<\/em> synthesis from dietary tryptophan (the kynurenine pathway) is slow and inefficient, cells rely primarily on the <strong>NAD<sup>+<\/sup> salvage pathway<\/strong> to recycle nicotinamide:<\/p>\n\n\n\n<pre class=\"wp-block-preformatted nm-diagram\">                           The NAD+ Salvage Pathway\n                                      \u2502\n               Nicotinamide (NAM) \u25c4\u2500\u2500\u2500\u2534\u2500\u2500\u2500 (Sirtuins, PARPs, CD38)\n                       \u2502\n             [ NAMPT Enzyme (Rate-Limiting) ]\n                       \u2502\n                       \u25bc\n         Nicotinamide Mononucleotide (NMN) \u25c4\u2500\u2500\u2500\u2500 Nicotinamide Riboside (NR)\n                       \u2502                              [ NRK Kinase ]\n             [ NMNAT Enzyme ]\n                       \u2502\n                       \u25bc\n                      NAD+<\/pre>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"the-contenders\">The Contenders:<\/h3>\n\n\n\n<ol class=\"wp-block-list\"><li><strong>Nicotinamide Riboside (NR):<\/strong> A nucleoside consisting of nicotinamide linked to a ribose ring. It enters cells via equilibrative nucleoside transporters (ENTs) and is phosphorylated by <strong>nicotinamide riboside kinases (NRK1 and NRK2)<\/strong> directly to form NMN, which is then converted to NAD<sup>+<\/sup>.<\/li><li><strong>Nicotinamide Mononucleotide (NMN):<\/strong> A nucleotide consisting of nicotinamide, ribose, and a 5&#8242;-phosphate group. While NMN was historically believed to require extracellular dephosphorylation to NR prior to cell entry, researchers identified a specific transporter (<strong>Slc12a8<\/strong>) in murine small intestine that can transport NMN directly across cell membranes.<\/li><li><strong>Intact NAD+:<\/strong> Contains an additional adenosine monophosphate group. Intact NAD<sup>+<\/sup> cannot easily cross plasma membranes without being dephosphorylated extracellularly by enzymes like CD73 to NMN or NR.<\/li><\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"oral-precursors-nr-vs-nmn-human-clinical-evidence\">Oral Precursors (NR vs NMN): Human Clinical Evidence<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Over the past five years, numerous double-blind, randomized, placebo-controlled clinical trials have evaluated oral NR and NMN in humans:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"1-nicotinamide-riboside-nr-trials\">1. Nicotinamide Riboside (NR) Trials<\/h3>\n\n\n\n<ul class=\"wp-block-list\"><li>Multiple published clinical studies (e.g. Martens et al., <em>Nature Communications<\/em>; Trammell et al.) confirm that oral NR (500 mg to 2000 mg daily) is safely tolerated and produces a dose-dependent, steady-state <strong>40% to 90% increase in whole-blood NAD<sup>+<\/sup><\/strong>.<\/li><li>In older adults, NR reduced systemic pro-inflammatory cytokines (IL-6, TNF-\u03b1) and lowered aortic stiffness, but produced modest or negligible effects on insulin sensitivity, mitochondrial respiration, and skeletal muscle strength.<\/li><\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"2-nicotinamide-mononucleotide-nmn-trials\">2. Nicotinamide Mononucleotide (NMN) Trials<\/h3>\n\n\n\n<ul class=\"wp-block-list\"><li>Clinical trials (e.g. Yoshino et al., <em>Science<\/em> 2021; Igarashi et al., <em>npj Aging<\/em> 2022) evaluated oral NMN (250 mg to 1000 mg daily) in middle-aged and older adults over 10 to 12 weeks.<\/li><li>In postmenopausal women with prediabetes, NMN significantly increased muscle insulin sensitivity (glucose disposal rate during hyperinsulinaemic-euglycemic clamps) and enhanced muscle remodeling gene expression.<\/li><li>A 2023 trial by Lin and colleagues demonstrated significant improvements in 6-minute walking test distance and subjective vitality scores in older adults receiving 600 mg daily.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"intravenous-iv-nad-infusions-science-and-practical-realities\">Intravenous (IV) NAD+ Infusions: Science and Practical Realities<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">In commercial wellness and anti-aging clinics, intravenous NAD<sup>+<\/sup> infusions (typically 250 mg to 1000 mg infused over 2 to 4 hours) have become widespread.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"what-happens-pharmacokinetically-during-an-iv-infusion\">What Happens Pharmacokinetically During an IV Infusion?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A landmark human clinical pharmacokinetic study published by Grant and colleagues in <em>Frontiers in Aging Neuroscience<\/em> (2019) tracked plasma and urine metabolites during a constant 750 mg IV NAD<sup>+<\/sup> infusion:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>During the first <strong>2 hours of infusion<\/strong>, no intact NAD<sup>+<\/sup> or nicotinamide was excreted in the urine, and plasma NAD<sup>+<\/sup> rose only marginally, indicating rapid tissue extraction and cellular binding.<\/li><li>After 2 hours, circulating levels of NAD<sup>+<\/sup>, nicotinamide, and methylated breakdown products (methylnicotinamide) spiked dramatically in plasma and urine.<\/li><\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"adverse-reactions-during-iv-infusion\">Adverse Reactions During IV Infusion<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Unlike oral precursors, intravenous NAD<sup>+<\/sup> infusion provokes immediate, intense autonomic and physical side effects if infused at standard drip rates:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Chest Tightness and Constriction:<\/strong> Sensation of heavy pressure on the sternum.<\/li><li><strong>Intense Abdominal Cramping and Nausea:<\/strong> Painful gut contractions and urge to defecate.<\/li><li><strong>Flushing and Headache:<\/strong> Throbbing temporal headache and peripheral vasodilation.<\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Biological Cause:<\/em> Extracellular NAD<sup>+<\/sup> and its breakdown product <strong>adenosine<\/strong> stimulate purinergic <strong>adenosine A1 and A2A receptors<\/strong> on cardiac pacemaker cells, coronary vasculature, and intestinal smooth muscle. To tolerate an infusion, the drip rate must be set very slow, typically requiring <strong>3 to 5 hours<\/strong> per session.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"subcutaneous-and-intramuscular-nad-injections\">Subcutaneous and Intramuscular NAD+ Injections<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Due to the length, cost, and discomfort of IV infusions, subcutaneous (SC) and intramuscular (IM) injections of sterile NAD<sup>+<\/sup> solution (typically 50 mg to 100 mg per injection, such as the NovaMeds NAD+ 300 and 600 preparations) have gained substantial clinical use:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Pharmacokinetics:<\/strong> Subcutaneous injection allows slow, continuous systemic absorption from the subcutaneous capillary bed over several hours, avoiding the acute plasma spikes that trigger severe chest pressure during rapid IV delivery.<\/li><li><strong>Local Discomfort:<\/strong> Subcutaneous injection frequently produces a localized, transient burning or stinging sensation at the injection site due to the acidic pH of concentrated NAD<sup>+<\/sup> solutions. Injecting slowly and using room-temperature solution mitigates discomfort.<\/li><li><strong>Research Status:<\/strong> While widely used in private clinical practice, large-scale randomized controlled trials directly comparing subcutaneous NAD<sup>+<\/sup> injection against oral NMN\/NR are still ongoing.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"safety-profile-methylation-demands-and-oncological-debates\">Safety Profile, Methylation Demands and Oncological Debates<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"1-the-methylation-pool-depletion-the-mthfr-link\">1. The Methylation Pool Depletion (The MTHFR Link)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">When high-dose NAD<sup>+<\/sup> or its precursors enter cells and are cleaved by sirtuins or PARPs, large quantities of <strong>nicotinamide (NAM)<\/strong> are released.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>To prevent high NAM concentrations from inhibiting sirtuins (via product inhibition), the body excretes excess NAM by methylating it into <strong>N-methylnicotinamide (MeNAM)<\/strong> via the liver enzyme <strong>nicotinamide N-methyltransferase (NNMT)<\/strong>.<\/li><li>NNMT requires S-adenosylmethionine (SAMe) as the universal methyl donor.<\/li><li><em>Clinical Concern:<\/em> Chronic mega-dosing of oral NAD<sup>+<\/sup> precursors (e.g. &gt;1000 mg daily) can deplete cellular methyl pools, potentially lowering choline, betaine, and elevating homocysteine. Many clinicians co-prescribe a methyl donor (such as <strong>trimethylglycine \/ TMG<\/strong>, 500 mg daily) alongside long-term NAD<sup>+<\/sup> therapies.<\/li><\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"2-the-theoretical-oncological-debate\">2. The Theoretical Oncological Debate<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Malignant tumor cells exhibit altered metabolism (the Warburg effect) and have high energy and DNA repair demands, making them voracious consumers of NAD<sup>+<\/sup>.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>While extensive clinical and preclinical trials have shown that NAD<sup>+<\/sup> precursors <strong>do not initiate de novo cancer<\/strong>, theoretical concerns remain that elevating systemic NAD<sup>+<\/sup> could support the survival or resistance of existing, pre-diagnosed malignant tumors.<\/li><li>Patients with active, untreated malignancies are advised to avoid high-dose NAD<sup>+<\/sup> supplementation.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"frequently-asked-questions\">Frequently Asked Questions<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"is-oral-nmn-legal-to-buy\">Is oral NMN legal to buy?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In late 2022, the US FDA determined that NMN could no longer be marketed as a dietary supplement in the United States because it was previously authorized for investigation as a new pharmaceutical drug (under an Investigational New Drug application). However, NMN remains widely sold in other international jurisdictions, and its physiological precursor, nicotinamide riboside (NR), remains fully permitted as a dietary supplement in both the US and Europe.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"can-i-just-take-high-dose-niacin-vitamin-b3-instead\">Can I just take high-dose niacin (vitamin B3) instead?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Standard niacin (nicotinic acid) can raise NAD<sup>+<\/sup> via the Preiss-Handler pathway, but high doses (&gt;1000 mg) trigger severe, uncomfortable cutaneous prostaglandin flushing and can cause hepatotoxicity, insulin resistance, and gout. Precursors like NR and NMN bypass the Preiss-Handler pathway and do not induce prostaglandin-mediated flushing.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"which-is-better-nmn-or-nr\">Which is better: NMN or NR?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Both molecules are effective at raising human cellular NAD<sup>+<\/sup> levels. In head-to-head clinical trials, both produce comparable increases in blood NAD<sup>+<\/sup>. Choice between them typically comes down to regional regulatory availability, formulation stability, and individual patient tolerance.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Related reading: <a href=\"https:\/\/novameds.health\/us\/knowledge-hub\/rapamycin-longevity-evidence\/\">Rapamycin (Sirolimus) for Longevity: mTOR Inhibition, Human Evidence and Safety<\/a> \u00b7 <a href=\"https:\/\/novameds.health\/us\/knowledge-hub\/what-are-peptides\/\">What Are Peptides? A Guide to Peptide Medicines and Research<\/a> \u00b7 <a href=\"https:\/\/novameds.health\/us\/knowledge-hub\/metformin-for-weight-loss\/\">Metformin for Weight Loss and Insulin Sensitivity: What the Evidence Shows<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"references\">Scientific references<\/h2>\n\n\n\n<ol class=\"nm-refs\"><li id=\"ref-1\"><strong>Cambronne ED, Kraus WL.<\/strong> <em>Location, Location, Location: Compartmentalization of NAD+ Synthesis and Functions in Mammalian Cells.<\/em> Trends in Biochemical Sciences. 2020;45(10):858-873. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32674966\/\">PubMed PMID: 32674966<\/a><\/li><li id=\"ref-2\"><strong>Chini CCS, et al.<\/strong> <em>The NADase CD38 is induced by factors secreted from senescent cells providing a potential link between senescence and age-related NAD+ decline.<\/em> Nature Metabolism. 2020;2(11):1345-1359. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33199853\/\">PubMed PMID: 33199853<\/a><\/li><li id=\"ref-3\"><strong>Grant R, et al.<\/strong> <em>A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+.<\/em> Frontiers in Aging Neuroscience. 2019;11:257. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31551752\/\">PubMed PMID: 31551752<\/a><\/li><li id=\"ref-4\"><strong>Martens CR, et al.<\/strong> <em>Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults.<\/em> Nature Communications. 2018;9(1):1286. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29599478\/\">PubMed PMID: 29599478<\/a><\/li><li id=\"ref-5\"><strong>Yoshino M, et al.<\/strong> <em>Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.<\/em> Science. 2021;372(6547):1224-1229. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33888596\/\">PubMed PMID: 33888596<\/a><\/li><\/ol>\n\n\n\n<p class=\"nm-article-note wp-block-paragraph\">This article is educational and does not constitute personalized treatment advice. Treatment decisions depend on individual circumstances and professional assessment.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nicotinamide adenine dinucleotide (NAD+) declines with age. We evaluate the cellular biology of the NAD+ salvage pathway, comparing oral precursors (NR, NMN) to intravenous infusions and reviewing human evidence.<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[95],"tags":[213],"class_list":["post-476","post","type-post","status-publish","format-standard","hentry","category-research","tag-nad"],"_links":{"self":[{"href":"https:\/\/novameds.health\/us\/wp-json\/wp\/v2\/posts\/476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/novameds.health\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/novameds.health\/us\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/novameds.health\/us\/wp-json\/wp\/v2\/comments?post=476"}],"version-history":[{"count":5,"href":"https:\/\/novameds.health\/us\/wp-json\/wp\/v2\/posts\/476\/revisions"}],"predecessor-version":[{"id":668,"href":"https:\/\/novameds.health\/us\/wp-json\/wp\/v2\/posts\/476\/revisions\/668"}],"wp:attachment":[{"href":"https:\/\/novameds.health\/us\/wp-json\/wp\/v2\/media?parent=476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/novameds.health\/us\/wp-json\/wp\/v2\/categories?post=476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/novameds.health\/us\/wp-json\/wp\/v2\/tags?post=476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}